meta_pixel
Tapesearch Logo
Log in
WSJ Tech News Briefing

TNB Tech Minute: Trump Administration Proposes Requiring Higher Wages for H-1B Visa Holders

WSJ Tech News Briefing

The Wall Street Journal

News, Tech News

4.31.7K Ratings

🗓️ 27 March 2026

⏱️ 3 minutes

🧾️ Download transcript

Summary

Plus: Novartis will buy allergy-drug developer Excellergy. And in markets, shares of Unity Software and Lumentum Holdings were on the rise. Danny Lewis hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0

I think the potential of Agenic is to rethink how work gets done overall.

0:05.0

It challenges all sorts of traditional orthodoxies around how organizations execute the work at hand.

0:11.3

That's Jason Gersatus, CEO of Deloitte U.S., talking about the transformational potential of A.Gentic AI.

0:17.9

Join him later to learn why agents are a game changer for businesses across industries.

0:24.5

Here's your afternoon, TNB Tech Minute, for Friday, March 27th. I'm Danny Lewis for the Wall Street Journal.

0:31.0

In its latest move to discourage companies from hiring foreign workers instead of Americans,

0:35.5

the Trump administration plans to require that companies

0:37.9

pay higher wages for people who come to the U.S. on visas for high-skilled employees, a popular

0:43.3

tool for tech companies. A new rule proposed by the Labor Department this week would lift the

0:48.2

minimum pay for software developers and other workers who come to the U.S. on some visas, including

0:53.2

the H-1B program. Pay floors could rise as high as 33 percent who come to the U.S. on some visas, including the H-1B program.

0:55.4

Pay floors could rise as high as 33 percent, according to the Labor Department's proposal.

1:00.5

Tech companies have long used H-1B visas to hire foreign nationals,

1:04.3

a tool they say is needed to offset worker shortages for high-skilled professionals.

1:08.7

Novartis says it agreed to purchase biotech firm Accelergy for up to $2 billion.

1:13.6

The deal would add a new approach to treating allergic diseases to the Swiss pharmaceutical

1:17.5

company's immunology pipeline, including a drug candidate in early-stage trials.

1:22.5

Accelurgy also recently launched a new drug called Rhapsodo for Chronic Hives with no known trigger.

1:28.3

It's the latest in a series of acquisitions by Novartis in recent months, as the company turns

1:32.8

to dealmaking to fill its drug pipeline and offset patent expirations.

1:37.4

And in stock markets today, gaming software company Unity raised its first quarter revenue

1:42.8

guidance and said it would exit the

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from The Wall Street Journal, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Wall Street Journal and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.